← The SEC Ephemeris: the whole map
Outlook Therapeutics ONS-5010 (bevacizumab-vikg)
In the graph: all 46 documents (290 pages).
- Application
- BLA 761320
- Ticker
- OTLK
- Product
- ONS-5010 (bevacizumab-vikg)
- Disease area
- Wet age-related macular degeneration
- Response path
- Formal dispute resolution
- Complete Response Letters
- December 30, 2025 · August 27, 2025
- Where it stands
- CRL citing lack of substantial evidence, then formal dispute resolution; won on appeal (2026).
Also in ophthalmology: Aldeyra Therapeutics
From FDA letters and SEC filings. Not investment or medical advice.